| Project/Area Number |
13470170
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE |
|---|
Principal Investigator |
TAKIGAWA Masahiro HAMAMATSU UNIVERSITY, SCHOOL OF MEDICINE, Dermatology, Professor, 医学部, 教授 (80115873)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SEO Naohiro HAMAMATSU UNIVERSITY, SCHOOL OF MEDICINE, Dermatology, Assistant, 医学部, 助手 (50283354)
|
|---|
| Project Period (FY) |
2001 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥14,300,000 (Direct Cost: ¥14,300,000)
Fiscal Year 2003: ¥4,200,000 (Direct Cost: ¥4,200,000)
Fiscal Year 2002: ¥4,900,000 (Direct Cost: ¥4,900,000)
Fiscal Year 2001: ¥5,200,000 (Direct Cost: ¥5,200,000)
|
|---|
| Keywords | CTL / Langerhans' cell / barrier-disrupted skin / percutaneous peptide immunization / regulatory T cell / cancer immunotherapy / melanoma / 腫瘍抗原ペプチド / 経皮免疫法 / HLA-A0201 / MART-1 / がんワクチン / 急性角質層破壊 / ランゲルハンス細胞 |
|---|
| Research Abstract |
Percutaneous peptide immunization is a method in which tumor-specific cytotoxic T lymphocytes (CTL) are primed in the lymph nodes and spleen following application of tumor peptides to corneum barrier-disrupted marine skin. Immunized mice are protected against subsequent challenge with corresponding tumors and suppress the growth of established tumors. CTL expansion after peptide application seems to be mediated by epidermal Langerhans' cells. In the human, disruption of permeability barrier by tape stripping also induces activation of epidermal Langerhans' cells. Thus, percutaneous peptide immunization provides a simple and noninvasive means of inducing potent antitumor immunity that may be exploited for cancer immunotherapy in the human.
|
